Trichostatin A (TSA)

Catalog No.S1045

Trichostatin A (TSA) Chemical Structure

Molecular Weight(MW): 302.4

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.

Size Price Stock Quantity  
USD 247 In stock
USD 447 In stock
USD 870 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

6 Customer Reviews

  • Gck expression in WT primary hepatocytes transduced with FOXO1 and KR-FOXO1 adenoviruses in the presence or absence of trichostatinA (TSA).

    Cell, 2017, 171(4):824-835.e18. Trichostatin A (TSA) purchased from Selleck.

    Effect of TSA, SAHA and silibinin alone and in combination on left panel: IF staining for p-histone H3 Ser 10 and p-MPM-2 Ser /Thr positive cells and a-tubulin for mitotic spindle and DAPI as nuclear stain in H1299 cells. Right panel: % positive p-histone H3 Ser 10 mitotic cells and expression of p-MPM-2 Ser /Thr protein levels in H1299 cells.

    Epigenetics 2012 7(10):1161-72. Trichostatin A (TSA) purchased from Selleck.

  • HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h, and their expression of GRP78, PERK-eIF2α axis and ATF4, ATF3, CHOP and DR5 proteins.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

    HCT116 p53 null cells were treated with different HDACIs (1 μM TSA, 5 μM M344, 1 μM MS-275, 5 mM But, 10 mM VPA) for 24 h. ATF4, ATF3, CHOP and DR5 proteins were measured by Western blot.

    Biochem Biophys Res Commun 2014 10.1016/j.bbrc.2014.01.184. Trichostatin A (TSA) purchased from Selleck.

  • (B) The mRNA level of PRRT2 in the presence of different concentrations of DAC and TSA.

    Biochem Biophys Res Commun, 2017, 485(2):454-460. Trichostatin A (TSA) purchased from Selleck.

    Western blot analysis of Acetyl-H3 and H3. 0-20μM TSA was added.

     

     

    2010 Dr. Zhang of Tianjin Medical University. Trichostatin A (TSA) purchased from Selleck.

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Targets
HDAC [1]
(Cell-free assay)
~1.8 nM
In vitro

Trichostatin A inhibits the proliferation of eight breast carcinoma cell lines including MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3 with mean IC50 of 124.4 nM (range, 26.4-308.1 nM), with more potency against cell lines that express ERα than the ERα-negative cell lines. Trichostatin A inhibits HDAC activity similarly in all the breast cancer cell lines with mean IC50 of 2.4 nM (range, 0.6-2.6 nM), and results in pronounced histone H4 hyperacetylation. [1] Unlike Trapoxin (TPX) and Chlamydocin which potently inhibit HDAC1 or HDAC4 but not HDAC6, Trichostatin A inhibits these HDACs to a similar extent with IC50 of 6 nM, 38 nM, and 8.6 nM, respectively. [2] Trichostatin A (100 ng/mL) treatment induces the expression of transforming growth factor β type II receptor (TβRII) in MIA PaCa-2 cells through the recruitment of p300 and PCAF into a Sp1-NF-Y HDAC complex that binds the DNA element of TβRII promoter, which is associated with a concomitant acetylation of Sp1 and an overall decrease in the amount of HDAC associated with the complex. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
HEK 293 NXz0fWRFTnWwY4Tpc44hSXO|YYm= NFPOVpQxNjgQvF2= MlnxNlRp NHv2bnhmfGijbn;s NYKzXpoz\W6qYX7j[ZMhTU6jQzDhZ4V1gWyjdHnvckBidmRiaX7jdoVie2W|IFXOZWMh[WK3bnThcoNmKGmwIITo[UB1d3SjbDDj[YxtKGy7c3H0[UBidmRiYYSgeIhmKGOnbHygd5Vz\mGlZR?= NFjl[IQzPTd6N{C3PS=>
TE13 NGXmUllHfW6ldHnvckBCe3OjeR?= NEDtWWMxNjQQvF2= MWGyOIg> M4e4cJVxNXKnZ4XsZZRmeyCUQWPTSlVCKGyndnXs MkXjNlU2Pzl4NkW=
TE13 M{nBd2Fxd3C2b4Ppd{BCe3OjeR?= MmnSNE4{|ryP M3fvWlI1cA>? NXu5TI9wcW6qaXLpeJMhfGinIHPlcIwheHKxbHnm[ZJifGmxbh?= NV32dHQzOjV3N{m2OlU>
MEFs NH7ENo9HfW6ldHnvckBCe3OjeR?= NYTEPW0{Pc7:TR?= NFXOeoUyPmh? MlrubY5kemWjc3XzJJRp\SCHUFXDJIF1fGGlaH3lcpQtKFSrcjDk[YxqfmW{eTDhcoQhfGinIHXm[olkcWWwY4mgc4YheGWmZYP0ZYwh\m:{bXH0bY9v NYHQXoRlOjV2OEK2N|Q>
SW480  NED3[HZHfW6ldHnvckBCe3OjeR?= MVewMlHPxE1? NXP1T29LPDiq M3X6cWROW09? M{DJZZJmfmW{c3XzJGVOXA>? M4WydFI2PDN2OUm3
PC3  MnLESpVv[3Srb36gRZN{[Xl? M4ns[lAvOc7:TR?= MVq0PIg> NWX3fXJ2TE2VTx?= Mnj5doV3\XK|ZYOgSW1V NV\rV3lMOjV2M{S5PVc>
SW480  MWfGeY5kfGmxbjDBd5NigQ>? NV\W[nNZOC5zzszN NEjBVVE1QGh? MYHEUXNQ NEn1b3difHSnboXheIV{KGmwdnHzbY9vKGGwZDDtbYdz[XSrb36= M2D3Z|I2PDN2OUm3
PC3  NEjLdohHfW6ldHnvckBCe3OjeR?= M2[5e|AvOc7:TR?= MnfXOFhp M{PYeWROW09? M2TJcIF1fGWwdXH0[ZMhcW64YYPpc44h[W6mIH3p[5JifGmxbh?= MV[yOVQ{PDl7Nx?=
SW480  MmraSpVv[3Srb36gRZN{[Xl? NHi5NXAxNjIQvF2= MonYOFhp Mlv0SG1UVw>? NVO4TJBPcW6mdXPld{BqdmO{ZXHz[UBw\iCKRFHDNUBidmRiSFTBR|Ihd25iU3z1[{Bo\W6nczDwdo9ud3Snch?= M1PXTVI2PDN2OUm3
PC3  MV\GeY5kfGmxbjDBd5NigQ>? NVvjPId7OC5zzszN MY[0PIg> NVz1OHQzTE2VTx?= M2faSIlv\HWlZYOgbY5kemWjc3Wgc4YhUESDQ{GgZY5lKEiGQVOyJI9vKFOudXeg[4Vv\XNicILvcY91\XJ? MWWyOVQ{PDl7Nx?=
A431 M3vq[2Fxd3C2b4Ppd{BCe3OjeR?= M{KzfVIwOTBxNUCvNVAxdk1? NHj6Z3U1QGh? NF;hdlhFVVOR MWDpcohq[mm2czD0bIUh[2WubDDndo94fGh? M2fMXFI2OzdzME[5
A431 MYTGeY5kfGmxbjDBd5NigQ>? NUnMUVhnPTCwTR?= MoPnNk83NzF{L{K0bC=> MoHLSG1UVw>? M4\VWoFkfGm4YYTld{BxOjFiYX7kJIlvcGmkaYTzJGFVTjNiZYjwdoV{e2mxbh?= M4rOSFI2OzdzME[5
MDA-MB-231 NFjLfYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn;1NE03ODCwTR?= M2LuTVI1cA>? MmjESG1UVw>? NILxVmtKSzVyIH;mJFExOG6P MV2yOVE6Ojd{MR?=
MCF7 NWnKeYV{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEjkVGQxNTZyMH7N NVPwb2VyOjSq M2PUNmROW09? MkjVTWM2OCCxZjC3OY5O MlrPNlUyQTJ5MkG=
SKOV-3 NWTadZRUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorLNU0yOM7:TR?= MXuyOIg> MWrEUXNQ MUfJR|UxKG:oIEWuOu69VQ>? NXnUNZlCOjVzNkm0PVE>
A549 NHHYZXFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmjONU0yOM7:TR?= NHr0bHQzPGh? NFLndnRFVVOR MoXJTWM2OCCxZjCzMlLPxE1? M2XX[|I2OTZ7NEmx
SKOV-3 NIPCZWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF3FXZAxNjFvMd88US=> MVm0PIg> MnzJSG1UVw>? NFzC[XhKSzVyIH;mJFAvP87:TR?= MonhNlUyPjl2OUG=
A549 NXPwcYtZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIrqWFIxNjFvMd88US=> NV7vfYo4PDiq MVzEUXNQ NYjtSZNyUUN3MDDv[kAxNjJ6zszN NVnEcok6OjVzNkm0PVE>
SKOV-3 NFfhbmpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYOwMlAyNTBwOd88US=> MYG3Nog> MYXEUXNQ MoLGTWM2OCCxZjCwMlMz|ryP MlTxNlUyPjl2OUG=
A549 MnTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUWwMlAyNTBwOd88US=> NY\CTHlxPzKq M4r6SWROW09? M1fnPWlEPTBib3[gNE4xPs7:TR?= M1rNRVI2OTZ7NEmx
HeLa NH7IVY9HfW6ldHnvckBCe3OjeR?= MWSyOVBvVQ>? MWmxOog> MYfEUXNQ MVXpcoNz\WG|ZYOgR3lROUFzIH3SUmEh\XiycnXzd4lwdsLi NIizPWgzPTFzNk[4PC=>
CNE2 NHfyXWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkP0NVAxNTZyMH7N NEW0ZmUzPC92OD:3Nog> MXjpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDpckBiKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK= MmCxNlQ6Pjl7MEG=
PC3 NG\0OJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnnlNVAxNTFyMEDuUS=> NYm3R21QOjSq M3vOZmlEPTBib3[gN|Axdk1? MYiyOFg2PDZ3OB?=
LNCaP NETyPFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHL4V2EyODBvMUCwNI5O M2fVS|I1cA>? NWfGVG5UUUN3MDDv[kA{ODCwTR?= NWmxfWZQOjR6NUS2OVg>
HeLa  MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2G0W|LPxE1? Mof2OFhp MlXq[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHHic5V1KDJ3JR?= NULwXlRyOjR6NE[xN|U>
HMEC-1  NF;BPXNHfW6ldHnvckBCe3OjeR?= M1[0U|MxOG6P MYWyOIg> NYHtTmRqcW6lcnXhd4V{KGW6cILld5Nqd25ib3dCpHZGT0[UM9MgcXJPSQ>? NUXwO4JHOjR5MUC2N|E>
HeLa M1XIRmZ2dmO2aX;uJGF{e2G7 NVzxcI91OW2P NF7tc2IxNjWq NF;WN3Vi[m:uaYPo[ZMhfGinIITveIFtKEiGQVOgZYN1cX[rdIm= MUSyOFcxPzR5NB?=
ACP02 M1HhVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXQNlUxNzN3MD:1NFBvVQ>? MlLjNlRp Ml:z[IVkemWjc3XzJINmdGxidnnhZoltcXS7IH;mJIFxeHKxeHntZZRmdHliN{FCpEUh[XRiMkWwxsBvVQ>? MnPyNlQ3Pjh3NEe=
ACP03 NVWyUWRKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW[yOVAwOzVyL{WwNI5O NXP5bJZ7OjSq M4\lPYRm[3KnYYPld{Bk\WyuII\pZYJqdGm2eTDv[kBieHC{b4jpcYF1\Wy7IEewxsAmKGG2IEK1NOKhdk1? NUjhTVN4OjR4Nki1OFc>
U87 GBM M1LiPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjxWoEyODBxM{CwM|UxOCCwTR?= NHrrTFA4OiCq M1rMRVExOCViZYToZY5wdA>? NHfRXVZz\WS3Y3XzJI1m[W5iY3XscEBvfW2kZYKgZpkhOzFuIEW0MEBidmRiNUlCpEU> NXHEdZdrOjR2NkS4OFE>
U87 GBM MUHGeY5kfGmxbjDBd5NigQ>? MknTNVAxNzVyMDDOcS=> MmW0OFghcA>? NGDybHAyODBnIHX0bIFvd2x? MmD0TY5lfWOnczDT[Y5me2OnbnPlMWxqc2ViQXz0[ZJifGmxboOgbY4hVnWlbHXhdkBOd3KyaH;sc4d6 Mk\yNlQ1PjR6NEG=
RPE NVv2V5JGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWLiVXR5OC5{L{CuOE8xNjhxMTFOwG0> MV6yOE81QC95MjDo MVvEUXNQ M33KbolvcGmkaYTzJJRp\SCycn;sbYZmemG2aX;uJIJ6KGOnbHygZ5lkdGViYYLy[ZN1 NYTyXo5tOjR2NU[2NFI>
HT29  NHnSOm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MljzNVgxKG6P NUK3TXpVPzJiaB?= MX\JR|UxKG:oIEG4NEBvVQ>? M1LPXlI1OzZ6Mk[1
hMSCs NWCxfWlYTnWwY4Tpc44hSXO|YYm= M13n[VYvOjVibl2= NWfre2hVOjRiaB?= NYPkZVNmTE2VTx?= NWXrW3lHe3SjYnnsbZpmeyCKaYP0c45mKEGlZYT5cIF1cW:wIHHu[EB1cGViRYjwdoV{e2mxbjDv[kBRdHW{aYDveIVvfCCJZX7ldy=> MVSyOFMyOjN3Nh?=
Huh7  NEHpVlhHfW6ldHnvckBCe3OjeR?= NWn2WVV4OC5zL{CuOU8yNjBizszN MUmyOIg> Mmj4d5VxeHKnc4Pld{B[XEiGQ{Kg[4Vv\SCneIDy[ZN{cW:w MoDENlQzPjl4N{K=
SKOV3 NF2z[mhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXPNE4xPS1{IN88US=> M3r4d|ExNzJ2L{S4JIg> NXnrdmJ[TE2VTx?= M3LERY1m\GmjdHXzJIdzd3e2aDDhdpJme3RiaX6gZUBkd26lZX70doF1cW:wLTDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ NXjBSnNnOjR{MkO4NFE>
A2780 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUmwMlA2NTJizszN NWj5R|RQOTBxMkSvOFghcA>? NEHlRVhFVVOR MXrt[YRq[XSnczDndo94fGhiYYLy[ZN1KGmwIHGgZ49v[2WwdILheIlwdi1iYX7kJJRqdWVvZHXw[Y5l\W62IH3hco5meg>? M1Xi[|I1OjJ|OECx
SRA01/04  MmP2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzWbVMxNjJizszN MWS0PEBp MXXEUXNQ M4K3fZN2eHC{ZYPz[ZMh[2WubDDwdo9tcW[ncnH0bY9vKHSqcn;1[4ghe3WycILld5NqdmdidHjlJHBKO0txQXv0MEBxOziPQWDLJIFv\CCHUluxM|Ihe2mpbnHsbY5oKHCjdHj3ZZl{ MXmyOFE2Pzh5OB?=
HLEB3 NHK4T2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIPpSnkxNjJizszN MXq0PEBp MXLEUXNQ NHK4RoV{fXCycnXzd4V{KGOnbHygdJJwdGmoZYLheIlwdiC2aILveYdpKHO3cIDy[ZN{cW6pIITo[UBRUTONL1HreEwheDN6TVHQT{BidmRiRWLLNU8zKHOrZ37hcIlv\yCyYYToe4F6ew>? NVOzVotKOjRzNUe4O|g>
SRA01/04  MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVOwMlQwOC56IN88US=> NEnBOJk1QCCq MUjEUXNQ NGr2TopqdmS3Y3XzJINmdGxiYYDvdJRwe2m| M4jHSFI1OTV5OEe4
HLEB3 NUnRbI9RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PkNVAvPC9yLkig{txO M2DRUFQ5KGh? M3j3dWROW09? NVvxN4xucW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NIP4eGgzPDF3N{i3PC=>
HCT116 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXKwMlIh|ryP NXjZT2VVOTJiaB?= MlTZ[Y5p[W6lZYOgZ4VtdCCjcH;weI9{cXNiaX7keYNm\CCkeTDyZYRq[XSrb36= MoLPNlQyOjJ{M{G=
CA46 NXvjNFgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{K5bFMwPi9zMj:yOE81QCCwTR?= MlrzOFghcA>? M2HQVolvcGmkaYTzJJRp\SClZXzsJJBzd2yrZnXyZZRqd25iYYSgNlQh[W6mIES4JI5OyqB? NUKzUXFtOjRyNkS5OVE>
PMNs NFjQbpFHfW6ldHnvckBCe3OjeR?= M{\IW|MxKG6P NG\uSFc1QCCq MlnCbY5pcWKrdIOg[YZn\XKxY4n0c5NqeyxiSFTBR{Bi[3Srdnn0fUBidmRiUnHjJIFkfGm4aYT5 MmnnNlM6QDh4MUe=
H1299 NWDQd5JYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXXqO2JPOcLizszNxsA> M{THb|I1NzR6L{eyJIg> M2C0N4V1cGGwb3y= MY\pcoNz\WG|ZYOgZ4VtdCCmZXH0bEBi\nSncjCyOIg> MkXZNlM6OTZ4MEm=
A549 Mnu1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXWwMlI2NzBwNT:xJO69VQ>? NGLDPVQzPC92OD:3NkBp MlrQ[ZRp[W6xbB?= MYTpcohq[mm2czD0bIUh[2WubDDndo94fGhiaX6gZ49v[2WwdILheIlwdiCjbnSgeIlu\S2mZYDlcoRmdnRibXHucoVz MXmyN|g3Pzl7MR?=
H1299 NUSxXZhzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPYTmpnOC5{NT:wMlUwOSEQvF2= NHjIZXkzPC92OD:3NkBp NVnTbplv\XSqYX7vcC=> NFrTUolqdmirYnn0d{B1cGViY3XscEBoem:5dHigbY4h[2:wY3XueJJifGmxbjDhcoQhfGmvZT3k[ZBmdmSnboSgcYFvdmW{ NEO2WYczOzh4N{m5NS=>
A549 MVzBdI9xfG:|aYOgRZN{[Xl? Mn;uNE42NzFizszN MWS0PEBp M4WxXoV1cGGwb3y= NHroUFVqdmS3Y3XzJINmdGxiYYDvdJRwe2m| NUPHb|ZsOjN6Nke5PVE>
H1299 MlrqRZBweHSxc3nzJGF{e2G7 MmfYNE42NzFizszN MoXGOFghcA>? NIrUdIJmfGijbn;s NUThXlVicW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?= NWnVe3JIOjN6Nke5PVE>
SUM149PT NUH2Xo1nT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVyyM|cvPS9zMDFOwG0> MXu0PEBp Mlv1SG1UVw>? MlzxbY5lfWOnczDj[YxtKGSnYYToJIF1KDJizszNJIlve2Wwc3n0bZZmdHl? NXLWbHplOjN5OUK2N|g>
SUM190PT NX3Ldmc5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1\udVUxNzFyMD:yOVAhdk1? NH;QcY81QCCq Mln4SG1UVw>? M2HPOIlv\HWlZYOgZ4VtdCCmZXH0bEBifCB3MDDuUUB{\W6|aYTpeoVtgQ>? MmG2NlM4QTJ4M{i=
HCT1 M1\U[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHS3U3YxNjJxMT6wM|UvOCEQvF2= M2DRbVEzNzJ2L{O2M|Q5KGh? Mmf4bY5lfWOnczDj[YxtKGSnYYToJIlvKGOxbnPlcpRz[XSrb36tJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= NX\3PINFOjN5N{CwNFA>
Lovo MljQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn[yNE4zNzFwMD:1MlAh|ryP NX;VSHpTOTJxMkSvN|YwPDhiaB?= NHq2VW5qdmS3Y3XzJINmdGxiZHXheIghcW5iY3;uZ4VvfHKjdHnvck0h[W6mIITpcYUu\GWyZX7k[Y51KG2jbn7ldi=> NXjjRXd6OjN5N{CwNFA>
AGS M4jZW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XJUVAvODF3LUGg{txO MVW3NkBp MWrpcoR2[2W|IHPlcIwh\GWjdHigZ49v[2WwdILheIlwdiCmZYDlcoRmdnSueR?= MWWyN|c1PTB{NB?=
Huh7 NH;ieopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWexJO69VQ>? M3;5cFI1KGh? Ml\BSG1UVw>? NXfQe2IzemWmdXPld{Bi[m:3dDCyNEUhfmmjYnnsbZR6yqB? MoDiNlM3PDN7M{O=
ECC1 M{j6OmZ2dmO2aX;uJGF{e2G7 MV:1NFAhdk1? NIXaRoE2KGR? NHTEOolFVVOR NGSyN2JqdmS3Y3XzJGwyS0GPwrDlfJBz\XO|aX;uJINwNXS{ZXH0cYVvfCC5aYToJFUuSXqjQx?= M1PPXlI{PTNyN{[5
HEC1A Mnz0SpVv[3Srb36gRZN{[Xl? MkK3OVAxKG6P MUm1JIQ> NE\EcXhFVVOR MnrxbY5lfWOnczDMNWNCVcLiZYjwdoV{e2mxbjDjc{11emWjdH3lcpQhf2m2aDC1MWF7[UN? NX3kb2s5OjN3M{C3Olk>
EN1 NF3TN21HfW6ldHnvckBCe3OjeR?= MnSxOVAxKG6P NWrDdG5mPSCm NFXTNWdFVVOR M1K3[Ylv\HWlZYOgUFFESU4EoHX4dJJme3Orb36gZ48ufHKnYYTt[Y51KHerdHigOU1CgmGF NY[3dHZ6OjN3M{C3Olk>
MFE296 M4HlO2Z2dmO2aX;uJGF{e2G7 MUS1NFAhdk1? NH;5fXE2KGR? M132O2ROW09? M1LmbIlv\HWlZYOgUFFESU4EoHX4dJJme3Orb36gZ48ufHKnYYTt[Y51KHerdHigOU1CgmGF NYXD[ZRXOjN3M{C3Olk>
HASMCs NHzlRotHfW6ldHnvckBCe3OjeR?= MknONE02ODBibl2= NGG3XFg3KGR? MVHkc5dvNXKnZ4XsZZRmeyC2aHWg[ZhxemW|c3nvckBw\iCKQVTDJIFv\CClZXzsJJZq[WKrbHn0fS=> Ml\yNlM2OTh2Nke=
U373 M3vi[mZ2dmO2aX;uJGF{e2G7 MUGwMlI2NzBwNT:xJO69VQ>? MXiyOEBp M2K2SYlv[3KnYYPld{BRWi2EIHX4dJJme3Orb36gZ48ufHKnYYTt[Y51KHerdHigOWF7[WSF NHrYOFMzOzR5NEG3NS=>
ARN8  NXX3R|hiTnWwY4Tpc44hSXO|YYm= NVz4bVZQOC5yNT2yJO69VQ>? M1vieVI1KGh? MmfWdoVlfWOnczD0bIUhcW6mdXP0bY9vKG:oIIC1N{1l\XCnbnTlcpQh\2WwZYOgZpkhVnW2bHnuMVM> M1m3eFI{PDdyNUSw
MCF7 MoXFSpVv[3Srb36gRZN{[Xl? NHO4OFcxNjB3LUKg{txO NGXq[5MzPCCq NXjtOlBLemWmdXPld{B1cGViaX7keYN1cW:wIH;mJJA2Oy2mZYDlcoRmdnRiZ3Xu[ZMh[nliToX0cIlvNTN? NIj4fo8zOzR5MEW0NC=>
H1299  MkWzSpVv[3Srb36gRZN{[Xl? MVGwMlM{6oDVMdMgxtVO NXf5WZVROjRxNEigbC=> MmjMSG1UVw>? MUHpcoNz\WG|ZYOgSU1k[WSqZYLpckBxem:2ZXnuJIxmfmWuczDkc5NmKGSncHXu[IVvfGy7 MlK5NlM1PjF7N{W=
H1299 NV7te4JwTnWwY4Tpc44hSXO|YYm= M3njUFAvPSEQvF2= NUjBRmltPDhiaB?= MoLUSG1UVw>? MlTtbY5pcWKrdIOgeIhmKG2rZ4LheI9zgSCyb4TlcpRq[WxiY3;tZolv\SC5aYToJJNqdGmkaX7pci=> NGXzSWEzOzR4MUm3OS=>
H1299 MlO4SpVv[3Srb36gRZN{[Xl? M2DOZ|AvPSEQvF2= NX\pN2lDPDhiaB?= MXHEUXNQ NWHs[25lcW6qaXLpeJMhfGinIHnueoF{cX[nbnXzd:KhKGOxbXLpcoUhf2m2aDDzbYxq[mmwaX6= NXrKdI1[OjN2NkG5O|U>
MG-63  MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\sVFAvOyEQvF2= NUPwNoRpOTJvOU[gbC=> M1rNR2ROW09? NF:wcIlqdmirYnn0d{B1cGViY3XscEBoem:5dHigZ48ufHKnYYTt[Y51KHerdHigcYV1\m:{bXnu MoXvNlM1PTF6MUe=
LM8 M33MfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWiwMlMh|ryP MXGxNk06PiCq NUHmeGhKTE2VTx?= NUPCTXVIcW6qaXLpeJMhfGinIHPlcIwh\3Kxd4ToJINwNXS{ZXH0cYVvfCC5aYToJI1mfG[xcn3pci=> NH\4XYEzOzR3MUixOy=>
K562 M1XzcGZ2dmO2aX;uJGF{e2G7 M123[|AvPSEQvF2= NXPHS|UyOjRiaB?= NF;obWJmfGijbn;s MX\k[YNz\WG|ZYOgeIhmKGWweont[UBi[3Srdnn0fUBw\iCKRFHDd{Bkdy22cnXheI1mdnRid3n0bEBkfXKldX3pci=> NGrmelQzOzR|MEm1Oy=>
HEL NVvad5VqTnWwY4Tpc44hSXO|YYm= MVqwMlUh|ryP Mnz3NlQhcA>? NUj1OZJ3\XSqYX7vcC=> M1nSc4Rm[3KnYYPld{B1cGViZX76fY1mKGGldHn2bZR6KG:oIFjERWN{KGOxLYTy[YF1dWWwdDD3bZRpKGO3cnP1cYlv NHHPfHQzOzR|MEm1Oy=>
HL60 NWDYcolsSXCxcITvd4l{KEG|c3H5 NFn2boUyKM7:TR?= Mo[xNlQhcA>? NXnGdmwycW6mdXPld:Kh[2WubDDk[YF1cA>? Ml71NlM1ODB3MUm=
KG1 MWfBdI9xfG:|aYOgRZN{[Xl? MUexJO69VQ>? NF64dXQzPCCq NX\WbGpkcW6mdXPld:Kh[2WubDDk[YF1cA>? NWKxXIZQOjN2MEC1NVk>
Kazumi MWfBdI9xfG:|aYOgRZN{[Xl? NWnVPWdROSEQvF2= M2fYTFI1KGh? MljKbY5lfWOnc9MgZ4VtdCCmZXH0bC=> MVOyN|QxODVzOR?=
K562 NEDBPWpCeG:ydH;zbZMhSXO|YYm= M3jrT|Eh|ryP NGXOepozPCCq MYPpcoR2[2W|wrDj[YxtKGSnYYTo M2r2d|I{PDByNUG5
THP1 NWr5NW16SXCxcITvd4l{KEG|c3H5 NULDe3poOSEQvF2= NYrjXYpxOjRiaB?= Mn\obY5lfWOnc9MgZ4VtdCCmZXH0bC=> MUKyN|QxODVzOR?=
SH-SY5Y NYXK[XNmTnWwY4Tpc44hSXO|YYm= MojuNlUxKG6P NIPPNVgyPiCq NWfmcWZD[2ijbnfld{BmgHC{ZYPzbY9vKHCjdITldo4hd2ZiZ3Xu[ZMhcW64b3z2[YQhcW5iY3jvcIV{fGW{b3ygd5lvfGinc3nzMEB2eHSja3WgZY5lKGWoZnz1fC=> NYmxTZB1OjN|Mk[0NlI>
HEK293 M2nBWmZ2dmO2aX;uJGF{e2G7 NILTVZAyKML3TdMg NGHyN|IyQCCqwrC= NX3IWHQ{cW6qaXLpeJMhfGinIHvhcIlzcW5vNz3t[YRq[XSnZDDy[YNzfWm2bXXueEBw\iC|eX7wbIltcW5vMTDh[4dz\WejdHXzJIlvfG9iYXfndoV{d22ncx?= M1zwbVI{Ojh2OES4
HTK MXLGeY5kfGmxbjDBd5NigQ>? NUTHSodnPDByIH7N MkXjO|IhcA>? NETVXJZqdmirYnn0d{BVT0ZvzsNihLNKdmS3Y3XkJG16d2[rYoLvZoxie3RiRHnm[oVz\W62aXH0bY9v NF;HXYMzOzJ6NECwNi=>
HTK NWCzN4hPTnWwY4Tpc44hSXO|YYm= NFzRc4YyODBvOECwcm0> M1O0S|czKGh? M{e4ToJtd2OtczDUS2Yu|rMkgKPJcoR2[2WmIGLPV{BidmRiSELPNuKhSWOldX31cIF1cW:w NGrTSJEzOzJ6NECwNi=>
Caco-2  NV7YOnpnTnWwY4Tpc44hSXO|YYm= M1fTRVEhyrWPwrC= NVm1fVFUOjRiaB?= M{Pzc4Rm[3KnYYPld{BUTVKWIIDyc5RmcW5iZYjwdoV{e2mxbh?= MoDYNlMyQTVyN{C=
HeLa MkHIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnYT5AyODBibl2= M1;2SFI1KGh? NEju[VlFVVOR MnrKTWM2OCCxZjCxNFBvVQ>? NVr5ZoNrOjNzNkW3OFg>
HeLa M{jG[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYC0NEBvVQ>? M4m4TFQ5KGh? M3rR[2ROW09? M3jY[2lEPTBib3[gOFBvVQ>? Mmf6NlMyPjV5NEi=
HeLa MmOyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NETiTHYzOCCwTR?= MlHZO|IhcA>? NVHxSpZTTE2VTx?= MoXRTWM2OCCxZjCyNI5O M2HBUlI{OTZ3N{S4
HeLa M4XSbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXSxNE8{OC93MDDuUS=> M1G4XFczKGh? NInF[FZFVVOR MXzpcoNz\WG|ZYOgeIhmKG63bXLldkBw\iCPTWCgLO6V|qivKTDsc5N{KGOnbHzzJIRwe2ViZHXw[Y5l\W62bIm= M3PpS|I{OTZ3N{S4
MDA-MB-231 NFPFUXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{P0dlI2NTRyMDDuUS=> MmLXOFghcA>? MVnJR|UxKG:oIEK2N{4zdk4EoB?= NILsR4UzOzB3NUG5PC=>
MCF-7  NETYfINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUXuVZpUOjVvNECwJI5O NUf4WXBXPDhiaB?= MnvWTWM2OCCxZjCyNlAvPG6P M2DxOlI{ODV3MUm4
ECC-1  M3;P[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWmxNFAhdk1? NH\4TowzPCCq NGTmbY9mfGijbn;s MU\pcoNz\WG|ZYOgeIhmKHC{b4DvdpRqd25ib3[gZZBweHSxdHnjJI52[2ynaTD0c{A{PSV? MVmyN|AzQDhyMx?=
HEC-1A MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVuwVWV[OTByIH7N MojXNlQhcA>? MYDleIhidm:u MX\pcoNz\WG|ZYOgeIhmKHC{b4DvdpRqd25ib3[gZZBweHSxdHnjJI52[2ynaTD0c{A{QSV? M2rVXFI{ODJ6OECz
NHAC-kn MoWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml;FNVAwOTByL{WwNEBvVQ>? M3fUOVEzKGh? MXjEUXNQ NIPiOFFKSzVyIH;mJFUxOG6P NF3qU|EzOzBzN{i3NS=>
A549 M2O4W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmrvNlUxKG6P MVm2MVczKGh? NYezRo9mTE2VTx?= NXXKSlBv[2G3c3XzJIEh\3KnYYTldkBqdmirYnn0c5J6KGWoZnXjeEBkd22kaX7lJJdqfGhiVGjUJI9zKGW{bH;0bY5q[g>? NX\uNZFtOjJ7OUS3PFA>
MG-63 NUO3OIlRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfqPWM{ODBibl2= MWmxNkBp M3G2bWROW09? M1u1NYlvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDD0c{A5PiV? NILDcnUzOjd7OUOzPC=>
MG-63 MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIG1WFg{ODBibl2= MofrNlQhcA>? NXjPVIVCTE2VTx?= NFX5PZVqdmirYnn0d{B1cGViY3XscEBoem:5dHigeI8hPjdn NH2zWJMzOjd7OUOzPC=>
MG-63 MlLnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWrVUpQ6OzByIH7N NGPaPXE1QCCq Mmq2SG1UVw>? M4DENYlvcGmkaYTzJJRp\SClZXzsJIdzd3e2aDD0c{A2PiV? Mki4NlI4QTl|M{i=
HL60  NYnrR2hmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmHRNVUxNTN3MDDuUS=> MU[yOEBp MmTGbY5kemWjc3XzJINmdGxiYYDvdJRwe2m|wrD3bIVvKGOxbnPlcpRz[XSrb37zJIhq\2incjD0bIFvKDJ3MDDuUS=> NUXPV5Q2OjJ5NUO3N|k>
U937 NUDoe4Q4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\DeoRZOTVyLUO1NEBvVQ>? MlHoNlQhcA>? NIT2clhqdmO{ZXHz[ZMh[2WubDDhdI9xfG:|aYRCpJdp\W5iY3;uZ4VvfHKjdHnvcpMhcGmpaHXyJJRp[W5iMkWwJI5O M16zOlIzPzV|N{O5
SCC-6 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jqfFIxOC1|MkCwJI5O NFHzbW0yOi9{ND:0PEBp M3j1VmROW09? MYDpcohq[mm2czD0bIUheHKxbHnm[ZJifGmxbjDv[kBUS0NvNjDj[YxteyCrbjDhJIRwe2VvIHHu[EB1cW2nLXTldIVv\GWwdDDtZY5v\XJ? M2HIS|IzPTV{M{Kx
U87  NWexPYJLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVG3VXhWOTByLUOwNEBv\w>? NWXGSpZuOjRiaB?= NF\2NGFqdmirYnn0d{B1cGViY3XscEBoem:5dHigeI8hPzJnIDDheEAzODCwZx?= MmPaNlIzPzB6NEm=
K562 NVvUZ2E6TnWwY4Tpc44hSXO|YYm= Mki2NUDPxE1? Mln1NVIhcA>? MYHEUXNQ NXf5[GlT\W6qYX7j[ZMhfGinIHX4dJJme3Orb36gc4YhWlWQWEOgbY5lfWOnZDDifUA2NWG8YT3D[HI> NUPCcWtZOjJzN{mxPVg>
Reh NY\5U49wTnWwY4Tpc44hSXO|YYm= NH7y[XkxNjNxMTFOwG0> MoXwNVIhcA>? NYDvdZBbTE2VTx?= M3rxT4VvcGGwY3XzJJRp\SCneIDy[ZN{cW:wIH;mJHJWVlh|IHnu[JVk\WRiYomgOU1igmFvQ3TS M37LUVIzOTd7MUm4

... Click to View More Cell Line Experimental Data

In vivo Administration of Trichostatin A at 0.5 mg/kg for 4 weeks displays potent antitumor activity in the N-methyl-N-nitrosourea carcinogen-induced rat mammary carcinoma model, without any measurable toxicity at doses up to 5 mg/kg. [1] Single intraperitoneal doses of 10 mg/kg Trichostatin A in nontransgenic and spinal muscular atrophy (SMA) model mice results in increased levels of acetylated H3 and H4 histones and modest increases in survival motor neuron (SMN) gene expression. Administration of Trichostatin A at 10 mg/kg/day improves survival, attenuates weight loss, and enhances motor behavior in the SMA model mice. [5]

Protocol

Kinase Assay:

[1]

+ Expand

In vitro HDAC activity:

Total cellular extracts are prepared from each breast cancer cell line (MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, or SK-BR-3). A 20 μL crude cell extract (~2.5 ×105 cells), in the presence of varying concentrations of Trichostatin A in 0.1% (v/v) ethanol or 0.1% (v/v) ethanol as vehicle control, are incubated for 60 minutes at 25 °C with 1 μL (~1.5 × 106 cpm) of [3H]acetyl-labeled histone H4 peptide substrate (NH2-terminal residues 2-20) that has been acetylated with [3H]acetic acid, sodium salt (3.7 GBq/mmol) by an in vitro incorporation method. Each 200 μL reaction is quenched with 50 μL of 1 M HCl/0.16 M acetic acid and extracted with 600 μL of ethyl acetate, and released [3H]acetate is quantified by scintillation counting. IC50 values are determined graphically using nonlinear regression to fit inhibition data to the appropriate dose-response curve.
Cell Research:

[1]

+ Expand
  • Cell lines: MCF-7, T-47D, ZR-75-1, BT-474, MDA-MB-231, MDA-MB-453, CAL 51, and SK-BR-3
  • Concentrations: Dissolved in absolute ethanol, final concentrations ~10 μM
  • Incubation Time: 96 hours
  • Method:

    Cells are exposed to various concentrations of Trichostatin A for 96 hours. After treatment, cell proliferation is estimated using the sulforhodamine B colorimetric assay. Cell viability is determined by trypan blue exclusion.


    (Only for Reference)
Animal Research:

[1]

+ Expand
  • Animal Models: Inbred virgin female (Ludwig/Wistar/Olac) rats bearing tumors induced with NMU
  • Formulation: Dissolved in DMSO
  • Dosages: ~5 mg/kg/day
  • Administration: Injection s.c.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 23 mg/mL (76.05 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
3mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 302.4
Formula

C17H22N2O3

CAS No. 58880-19-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03185429 Not yet recruiting Tumor Gastric|Tumor Colorectal BGI China|Fujian Cancer Hospital December 2017 Not Applicable
NCT02959905 Recruiting Metastatic Melanoma BGI China|Sun Yat-sen University December 2016 Phase 1
NCT02695758 Completed Osteoarthritis: Shoulder Rothman Institute Orthopaedics December 2014 Not Applicable
NCT00158418 Completed Osteoarthritis Fowler Kennedy Sport Medicine Clinic|Zimmer Biomet August 2002 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I would like to obtain the enantiomers of TSA, as separate chemicals: R-TSA and S-TSA. Do you have any ideas?

  • Answer:

    Our S1045 Trichostatin A (TSA) is R enantiomer.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products5

Tags: buy Trichostatin A (TSA) | Trichostatin A (TSA) supplier | purchase Trichostatin A (TSA) | Trichostatin A (TSA) cost | Trichostatin A (TSA) manufacturer | order Trichostatin A (TSA) | Trichostatin A (TSA) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID